Company news

Rakovina Therapeutics Inc (TSXV:RKV) news

Rakovina Therapeutics Inc news releases on 6ix. Latest, Oct 1, 2026: Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI…

Rakovina Therapeutics Inc (TSXV:RKV) news

Press releases & updates

Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement

Rakovina Therapeutics Announces $1.5 Million Private Placement

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference

Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

Rakovina Therapeutics Announces Stock Option Grants

Rakovina Therapeutics Announces Warrant Exercise Incentive Program

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

Rakovina Therapeutics Announces Share Consolidation&#xA0;Effective Date

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation

Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as&#xA0;Chief Financial Officer

Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces Share Consolidation Effective Date

Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer